A Novel Urinary Metabolite Signature for Non-invasive Post-stroke Depression Diagnosis

Cell Biochemistry and Biophysics

Volumn 72, Issue 3, 2015, Pages 661-667

  Zhang, Wei ^a   Zhang, Xin an ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG SPORT UNIVERSITY   (China)

Author keywords

GC MS; Metabolomics; Post stroke depression

Indexed keywords

5-HYDROXYHEXANOIC ACID; AZELAIC ACID; BIOLOGICAL MARKER; DICARBOXYLIC ACID; GLYCERIC ACID; HEXANOIC ACID DERIVATIVE; HYDROXYACID; PHENYLALANINE; PSEUDOURIDINE; TYROSINE;

AGED; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COMPLICATION; DEPRESSION; FEMALE; HUMAN; MALE; METABOLOME; MIDDLE AGED; URINE;

AGED; BIOMARKERS; CAPROATES; CASE-CONTROL STUDIES; DEPRESSION; DICARBOXYLIC ACIDS; FEMALE; GLYCERIC ACIDS; HUMANS; HYDROXY ACIDS; MALE; METABOLOME; MIDDLE AGED; PHENYLALANINE; PSEUDOURIDINE; STROKE; TYROSINE;

EID: 84933676839     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-0472-9     Document Type: Article

References (30)

1. Kotila, M., Numminen, H., Waltimo, O., & Kaste, M. (1998). Depression after stroke: Results of the Finnstroke Study. Stroke,29, 368–372.
2. Hackett, M. L., Yapa, C., Parag, V., & Anderson, C. S. (2005). Frequency of depression after stroke a systematic review of observational studies. Stroke,36, 1330–1340.
3. Tu, W. J., Dong, X., Zhao, S. J., Yang, D. G., & Chen, H. (2013). Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. Journal of Neuroendocrinology,25, 771–778.
4. King, R. B. (1996). Quality of life after stroke. Stroke,27, 1467–1472.
5. Schmid, A., Kroenke, K., Hendrie, H., Bakas, T., Sutherland, J., et al. (2011). Poststroke depression and treatment effects on functional outcomes. Neurology,76, 1000–1005.
6. Saxena, S. K., Ng, T. P., Koh, G., Yong, D., & Fong, N. P. (2007). Is improvement in impaired cognition and depressive symptoms in post-stroke patients associated with recovery in activities of daily living? Acta Neurologica Scandinavica,115, 339–346.
7. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (pp. 300–396). American Psychiatric Publishing.
8. Chen, L. S., Eaton, W. W., Gallo, J. J., & Nestadt, G. (2000). Understanding the heterogeneity of depression through the triad of symptoms, course and risk factors: A longitudinal, population-based study. Journal of Affective Disorders,59, 1–11.
9. Berg, A., Lönnqvist, J., Palomäki, H., & Kaste, M. (2009). Assessment of depression after stroke. Stroke,40, 523–529.
10. Schubert, D. S., Burns, R., Paras, W., & Sioson, E. (1992). Increase of medical hospital length of stay by depression in stroke and amputation patients: A pilot study. Psychotherapy and Psychosomatics,57, 61–66.
11. Kaddurah-Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008). Metabolomics: A global biochemical approach to drug response and disease. Annual Review of Pharmacology and Toxicology,48, 653–683.
12. Nicholson, J. K., & Lindon, J. C. (2008). Systems biology: Metabonomics. Nature,455, 1054–1056.
13. Jung, J. Y., et al. (2011). 1H-NMR-based metabolomics study of cerebral infarction. Stroke,42, 1282–1288.
14. Yang, J., et al. (2011). Potential metabolite markers of schizophrenia. Molecular Psychiatry,18, 67–78.
15. Chen, Jian-jun, Liu, Zhao, Fan, Song-hua, Yang, De-yu, Zheng, Peng, Shao, Wei-hua, et al. (2014). Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. Scientific Reports,. doi:10.1038/srep05855.
16. Zheng, Peng, Chen, Jian-jun, Huang, Ting, Wang, Ming-ju, Wang, Ying, Jun, Mu, et al. (2013). A novel urinary metabolite signature for diagnosing major depressive disorder. Journal of Proteome Research,12(12), 5904–5911.
17. Fang, J., Yan, W., Jiang, G. X., Li, W., & Cheng, Q. (2011). Serotonin transporter gene polymorphism in chinese patients with poststroke depression a case-control study. Stroke,42, 1461–1463.
18. Shao, W. H., et al. (2012). Metabolomic identification of molecular changes associated with stress resilience in the chronic mild stress rat model of depression. Metabolomics,9, 433–443.
19. Luedemann, A., Strassburg, K., Erban, A., & Kopka, J. (2008). TagFinder for the quantitative analysis of gas chromatography mass spectrometry (GC-MS)-based metabolite profiling experiments. Bioinformatics,24(5), 732–737.
20. Domenici, E., Willé, D. R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., et al. (2010). Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One,5(2), e9166.
21. Mahadevan, S., Shah, S. L., Marrie, T. J., & Slupsky, C. M. (2008). Analysis of metabolomic data using support vector machines. Analytical Chemistry,80(19), 7562–7570.
22. Qi, Y., Li, P., Zhang, Y., Cui, L., Guo, Z., Xie, G., et al. (2012). Urinary metabolite markers of precocious puberty. Molecular & Cellular Proteomics,11(1), M111.011072.
23. Zheng, P., et al. (2013). Novel urinary biomarkers for diagnosing bipolar disorder. Metabolomics,9, 800–808.
24. Bradley, A. P. (1997). The use of the area under the ROC curve in the evaluation of machine learning algorithms. Pattern Recognition,30, 1145–1159.
25. Ge, Y., Sealfon, S. C., & Speed, T. P. (2008). Some step-down procedures controlling the false discovery rate under dependence. Statistica Sinica,18, 881.
26. Micheel, C. (2012). Evolution of translational omics: Lessons learned and the path forward (Institute ofMedicine Consensus Report). Washington: National Academies Press.
27. Xu, X. J., et al. (2014). 2, 4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder. Molecular BioSystems,10, 813–819.
28. Papakostas, G., Shelton, R., Kinrys, G., Henry, M., Bakow, B., Lipkin, S., et al. (2013). Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: A pilot and replication study. Molecular Psychiatry,18, 332–339.
29. Spijker, S., Van Zanten, J. S., De Jong, S., Penninx, B. W., van Dyck, R., Zitman, F. G., et al. (2010). Stimulated gene expression profiles as a blood marker of major depressive disorder. Biological Psychiatry,68(2), 179–186.
30. Williams, R., et al. (2006). A multi-analytical platform approach to the metabonomic analysis of plasma from normal and Zucker (fa/fa) obese rats. Molecular BioSystems,2, 174–183.